Filing Details
- Accession Number:
- 0001209191-23-036261
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-06-12 16:13:40
- Reporting Period:
- 2023-06-08
- Accepted Time:
- 2023-06-12 16:13:40
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1664710 | Keros Therapeutics Inc. | KROS | Pharmaceutical Preparations (2834) | 811173868 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1682068 | Keith Regnante | C/O Keros Therapeutics, Inc. 1050 Waltham Street, Suite 302 Lexington MA 02421 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-06-08 | 20,000 | $16.00 | 20,000 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-06-08 | 17,301 | $47.66 | 2,699 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-06-08 | 2,699 | $48.65 | 0 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2023-06-09 | 20,000 | $16.00 | 20,000 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-06-09 | 15,993 | $45.03 | 4,007 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-06-09 | 1,428 | $46.46 | 2,579 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-06-09 | 2,579 | $47.25 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2023-06-08 | 20,000 | $0.00 | 20,000 | $16.00 |
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2023-06-09 | 20,000 | $0.00 | 20,000 | $16.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 113,622 | 2030-04-06 | No | 4 | M | Direct | |
| 93,622 | 2030-04-06 | No | 4 | M | Direct |
Footnotes
- This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.12 to $48.095 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.12 to $48.935 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.995 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.015 to $47.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.015 to $47.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- One-fourth (1/4th) of the shares subject to the option shall vest on February 24, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.
Billionaire Hedge Funds
